Literature DB >> 33691626

Isolation of Mycobacterium talmoniae from a patient with diffuse panbronchiolitis: a case report.

Tomoko Suzuki1, Miwako Saitou2, Yuriko Igarashi3, Satoshi Mitarai3, Katsunao Niitsuma2.   

Abstract

BACKGROUND: Mycobacterium (M) talmoniae isolated from a patient with cystic fibrosis was first described in 2017, and cases of M. talmoniae remain exceedingly rare. CASE
PRESENTATION: A 51-year-old woman had respiratory symptoms for 10 years. Diffuse panbronchiolitis (DPB) was detected at the first visit at our hospital. A cavity lesion in the apex of the left lung was found, and sputum and bronchoalveolar lavage fluid were acid-fast bacillus (AFB) smear- and culture-positive besides Pseudomonas aeruginosa. M. talmoniae was finally identified, and the standard combination therapy for non-tuberculous mycobacteria (NTM) was administered for 2 y referring to the drug-susceptibility test. Thereafter, the AFB culture was negative, the wall thickness of the lung cavity was ameliorated, and oxygen saturation improved.
CONCLUSIONS: We encountered a rare case of M. talmoniae with DPB, for which standard combination therapy was effective. M. talmoniae may be considered a potential pathogen of lung disease, especially in patients with bronchiectatic lesions.

Entities:  

Keywords:  Diffuse panbronchiolitis; Drug-susceptibility; Mycobacterium talmoniae; Non-tuberculous mycobacteria; Standard combination therapy

Mesh:

Year:  2021        PMID: 33691626      PMCID: PMC7945688          DOI: 10.1186/s12879-021-05944-9

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  18 in total

1.  Diffuse panbronchiolitis: a very rare disease in Western countries.

Authors:  Yamilex Urbano Aranda; Isabel García San José; Encarnación López Gabaldón
Journal:  Arch Bronconeumol       Date:  2012-02-18       Impact factor: 4.872

2.  Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin.

Authors:  S Kudoh; A Azuma; M Yamamoto; T Izumi; M Ando
Journal:  Am J Respir Crit Care Med       Date:  1998-06       Impact factor: 21.405

3.  Nontuberculous mycobacteria in diffuse panbronchiolitis.

Authors:  Takahiro Tsuji; Eisaku Tanaka; Ikkoh Yasuda; Yoshinari Nakatsuka; Yusuke Kaji; Takehiro Yasuda; Seishu Hashimoto; Moon Hee Hwang; Takashi Hajiro; Yoshio Taguchi
Journal:  Respirology       Date:  2014-09-30       Impact factor: 6.424

4.  Mycobacterium talmoniae sp. nov., a slowly growing mycobacterium isolated from human respiratory samples.

Authors:  Rebecca M Davidson; Mary Ann DeGroote; Jamie L Marola; Sarah Buss; Victoria Jones; Michael R McNeil; Alison G Freifeld; L Elaine Epperson; Nabeeh A Hasan; Mary Jackson; Peter C Iwen; Max Salfinger; Michael Strong
Journal:  Int J Syst Evol Microbiol       Date:  2017-08-15       Impact factor: 2.747

Review 5.  Diffuse panbronchiolitis.

Authors:  V Poletti; G Casoni; M Chilosi; M Zompatori
Journal:  Eur Respir J       Date:  2006-10       Impact factor: 16.671

6.  [Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis].

Authors:  A Yamanaka; S Saiki; S Tamura; K Saito
Journal:  Naika       Date:  1969-03

Review 7.  Genetic predisposition to diffuse panbronchiolitis.

Authors:  Naoto Keicho; Minako Hijikata
Journal:  Respirology       Date:  2011-05       Impact factor: 6.424

8.  [A case of recurrent aspiration pneumonia by achalasia].

Authors:  Masahiro Hirata; Kenji Kohno; Sadatsugu Murakami; Seiichi Yoneda; Yoshihiro Kajita; Youichi Fujita; Jirou Hirai; Keisuke Nakaji; Takashi Miyauchi
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2002-02

9.  Fatal pulmonary infection due to Mycobacterium fortuitum.

Authors:  M P Lessing; M M Walker
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

Review 10.  Diffuse panbronchiolitis: role of macrolides in therapy.

Authors:  Naoto Keicho; Shoji Kudoh
Journal:  Am J Respir Med       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.